← Back to Screener
NeOnc Technologies Holdings, Inc. Common Stock (NTHI)
Price$5.02
Favorite Metrics
Price vs S&P 500 (26W)-61.31%
Price vs S&P 500 (4W)-42.20%
Market Capitalization$122.84M
All Metrics
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)25.98%
Cash Flow / Share (Quarterly)$-0.91
Price vs S&P 500 (YTD)-40.25%
EPS (TTM)$-3.20
10-Day Avg Trading Volume0.06M
EPS Excl Extra (TTM)$-3.20
EPS (Annual)$-3.20
Gross Margin (Annual)100.00%
Cash / Share (Quarterly)$0.08
ROA (Last FY)-348.19%
EBITD / Share (TTM)$-2.99
Cash Flow / Share (Annual)$-0.22
Net Income / Employee (Annual)$-21
Net Interest Coverage (TTM)-17.90x
ROA (TTM)-1032.75%
EPS Incl Extra (Annual)$-3.20
Current Ratio (Annual)0.25x
Quick Ratio (Quarterly)0.15x
3-Month Avg Trading Volume0.06M
52-Week Price Return-35.09%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)3071.77x
Asset Turnover (Annual)0.02x
52-Week High$12.99
EPS Excl Extra (Annual)$-3.20
26-Week Price Return-57.32%
Quick Ratio (Annual)0.20x
13-Week Price Return-46.53%
Current Ratio (Quarterly)0.19x
Enterprise Value$126.028
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-155404.38%
Cash / Share (Annual)$0.00
3-Month Return Std Dev80.31%
Net Income / Employee (TTM)$-21
Net Interest Coverage (Annual)-16.62x
EPS Basic Excl Extra (Annual)$-3.20
EPS Incl Extra (TTM)$-3.20
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-64.92%
Year-to-Date Return-37.61%
5-Day Price Return0.78%
EPS Normalized (Annual)$-3.20
Net Profit Margin (Annual)-155404.38%
Month-to-Date Return-26.39%
EBITD / Share (Annual)$-3.03
Operating Margin (Annual)-145637.53%
EPS Basic Excl Extra (TTM)$-3.20
Price vs S&P 500 (13W)-47.22%
Beta2.00x
Revenue / Share (TTM)$0.00
52-Week Low$3.20
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
NTHINeOnc Technologies Holdings, Inc. Common Stock | — | — | — | — | $5.02 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
NeOnc Technologies develops molecular technology for targeted drug delivery to treat central nervous system diseases. The company's lead candidate, NEO100, is in Phase 2a clinical trials for glioblastoma and has received Orphan Drug and Fast Track designations from the FDA.